-transparent.png){kind=logo}
Various anthraquinones substituted with hydroxyl, amino, halogen, carboxylic acid, substituted aromatic group, and sulfonate were tested to determine their activity against human immunodeficiency virus type 1 (HIV-1) in primary human lymphocytes. Among the compounds tested, polyphenolic and/or polysulfonate substituted anthraquinones were found to possess the most potent antiviral activity. Hypericin, an anthraquinone dimer previously shown to have activity against nonhuman retroviruses also exhibited anti-HIV-1 activity in lymphocytes. the active anthraquinones inhibited HIV-1 reverse transcriptase. However, this enzyme inhibition was selective only for 1,2,5,8-tetrahydroanthraquinone and hypericin. Hypericin interacts nonspecifically with protein suggesting that this effect may dictate its inhibitory activity against the viral reverse transcriptase.
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
January 1988,
Ugeskrift for laeger,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
July 1988,
Antimicrobial agents and chemotherapy,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
December 1992,
Molecular pharmacology,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
December 1999,
Mayo Clinic proceedings,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
June 1992,
Antiviral research,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
January 1996,
Life sciences,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
January 1990,
Annals of the New York Academy of Sciences,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
December 2020,
Life (Basel, Switzerland),
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
January 1991,
Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
R F Schinazi, and
C K Chu, and
J R Babu, and
B J Oswald, and
V Saalmann, and
D L Cannon, and
B F Eriksson, and
M Nasr
April 1993,
Antimicrobial agents and chemotherapy,
